Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma (original) (raw)

Abstract

We conducted a phase II evaluation of fazarabine 1.75–2.0 mg/m2hr over 72 hours every 28 days in 14 previously untreated patients with advanced adenocarcinoma of the pancreas. The intial dose was 1.75 mg/m2/hr in 10 patients, and 2.0 mg/m2hr in 4 patients. The dose was escalated in 8 patients, including all 4 who started at the higher dose level. Toxicity was unexpectedly mild. The median WBC nadir was 4.4 (range: 2.4–15.8)×103/_μ_l, the median absolute neutrophil nadir was 3.2 (range: 0.9–13.0)×103/_μ_l, and the median platelet count was 134.0 (range: 48.0–291.0)×103/_μ_l. Gastrointestinal toxicity was generally mild. No major responses were seen, excluding, with 95% confidence, a response rate in excess of 20%.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Boring CC, Squires TS, Tong T: Cancer statistics 1991. CA-A Journal for Clinicians 41:19–36, 1991
    Google Scholar
  2. Cullinan SA, Moertel CG, Gleming TR,et al.: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinomas. JAMA 253:2061–2067, 1985
    PubMed Google Scholar
  3. Oster M, Gray R, Panasci L,et al.: Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin (FSM). Cancer 57:29–33, 1986
    PubMed Google Scholar
  4. Gastrointestinal Tumor Study Group: Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouacil. J Clin Oncol 4:1794–1798, 1986
    Google Scholar
  5. Beisler JA, Abbasi MM, Driscoll JS: The synthesis and antitumor activity of arabinosyl-5-azacytosine. Biochem Pharm 26:2469–2472, 1977
    PubMed Google Scholar
  6. Vesley J, Piskala A: Mechanism of action of 1-B-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells. Neoplasma 33:3–10, 1986
    PubMed Google Scholar
  7. Townsend A, Leclerc JM, Dutschman G,et al.: Metabolism of 1-B-D-arabinofuranosyl-5-azacytosine and incorportation into DNA of human T-lymphoblastic cells (Molt-4). Cancer Res 45:3522–3528, 1985
    PubMed Google Scholar
  8. Grazer RI, Knode MC: 1-B-D-arabinosyl-5-azacytosine: Cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells. Mol Pharmacol 26:381–387, 1984
    PubMed Google Scholar
  9. Dalal M, Plowman J, Breitman TR,et al.: Arabinofuranosyl-5-azacytosine: Antitumor and cytotoxic properties. Cancer Res 46:831–838, 1986
    PubMed Google Scholar
  10. Clinical brochure: Fazarabine (Ara-AC), NSC 281272. DCT, National Cancer Institute, Bethesda, MD/January 1987
  11. Ahluwalia G, Cohen MB, Kang CJ,et al.: Arabinosyl-5-azacytosine: Mechanisms of native and acquired resistance. Cancer Res 46:4479–4485, 1986
    PubMed Google Scholar
  12. Surbone A, Ford H Jr., Kelley JA,et al.: Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytidine (fazarabine, NSC 281272). Cancer Res 50:1220–1225, 1990
    PubMed Google Scholar
  13. Amato R, Raber M, Newman R. Ho D., Schmidt S, McElvey E: Phase I study of 5-azacytosine arabinoside (Ara-AC, fazarabine). Proc AACR 29:194, 1988
    Google Scholar
  14. Brown NS, Lin JR, Newman RA,et al.: Clinical pharmacology of fazarabine. Proc AACR 30:249, 1989
    Google Scholar
  15. Miller AB, Hoogstraten B, Staquet M: Reporting the results of cancer treatment. Cancer 47:207–214, 1981
    PubMed Google Scholar
  16. Ben-Baruch N, Denicoff A, Goldspiel J, O'Shaughnessy J, Cowan K: Phase II trial of fazarabine (F) in colon cancer (CC) and breast cancer (BC). Proc ASCO 10:68, 1991
    Google Scholar
  17. Tan C, Wollner N, Tong W, Steinherz P, Redner A: Phase I study of fazarabine (NSC 281272) in children with leukemia and lymphoma. Proc AACR 32:180, 1991
    Google Scholar

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York, New York, USA
    Ephraim S. Casper, Gary K. Schwartz & David P. Kelsen

Authors

  1. Ephraim S. Casper
  2. Gary K. Schwartz
  3. David P. Kelsen

Rights and permissions

About this article

Cite this article

Casper, E.S., Schwartz, G.K. & Kelsen, D.P. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.Invest New Drugs 10, 205–209 (1992). https://doi.org/10.1007/BF00877247

Download citation

Key words